PG
PCRX icon

PEAK6 Group’s Pacira BioSciences PCRX Stock Holding History

PEAK6 Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,500
Closed -$358K – 4877
2017
Q2 		$358K Buy
+7,500
New +$348K ﹤0.01% 2832
2016
Q2 		– Sell
-20,000
Closed -$1.06M – 4646
2016
Q1 		$1.06M Buy
+20,000
New +$1.17M 0.01% 1618
2015
Q4 		– Sell
-23,900
Closed -$982K – 5165
2015
Q3 		$982K Sell
23,900
-5,300
-18% -$325K 0.01% 2206
2015
Q2 		$2.06M Buy
29,200
+16,500
+130% +$1.3M 0.01% 1447
2015
Q1 		$1.13M Buy
+12,700
New +$1.29M 0.01% 1774
2014
Q4 		– Sell
-2,100
Closed -$204K – 5024
2014
Q3 		$204K Buy
+2,100
New +$204K ﹤0.01% 3287
2014
Q2 		– Sell
-500
Closed -$35K – 5002
2014
Q1 		$35K Buy
+500
New +$34K ﹤0.01% 4416

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

PEAK6 Group's PCRX Position: Q3 2017 in Review

PEAK6 Group sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 3,571 shares — an estimated $170K sold.

PEAK6 Group first reported a position in PCRX in Q3 2013 and held it in 6 quarters. The position peaked at $1.31M in Q3 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • PEAK6 Group reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • PEAK6 Group sold 3,571 Pacira BioSciences shares in Q3 2017, an estimated $170K.
  • PEAK6 Group first reported a position in Pacira BioSciences in Q3 2013 and held it in 6 quarters.
  • PEAK6 Group's Pacira BioSciences position peaked at $1.31M in Q3 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on PEAK6 Group's 13F filing for Q3 2017, filed 14 Nov 2017.